Top Toronto, Ontario Biotech Companies (33)
The best anti-aging resource is your own younger cells. Personalized regenerative medicine is the opportunity to leverage strategies that tap into the power of our own cells to treat our bodies. Our cells have the potential to rejuvenate skin, replenish hair, and even help fight disease. Preserving your own cells today can give you access to your own younger cells to use in revolutionary treatments for the rest of your life.
Rapid Novor Inc. is the world's leader in antibody protein sequencing technology. Specializing in the field of mass spectrometry-based proteomics, the team has developed the technology to directly sequence antibody proteins without needing to access the producing cell line. As a University of Waterloo spin-off, the company is building its technology portfolios based on the twenty years of scientific research and inventions from Dr. Bin Ma, co-founder and chief scientist. The company's REmAb™ antibody protein sequencing service has allowed for the accurate sequencing of any given antibody proteins on a routine basis. The company's WILD™ service is the first commercially available service that can accurately distinguish the isobaric Isoleucine and Leucine using mass spectrometry. The company's mission is to advance life science for better human health with next generation protein sequencing. For more information, visit www.rapidnovor.com. Follow the company on Twitter @rapidnovor.
Nicoya is a Canadian biotechnology company dedicated to improving human life by helping scientists succeed. Established in 2012, Nicoya was founded by Ryan Denomme in his relentless pursuit to use nanotechnology to increase the affordability and ease of use of scientific instruments. Within 10 years, Nicoya has grown to a team of 100+ employees who have extensive experience working at the forefront of nanotechnology and biotechnology sectors. Nicoya develops innovative and accessible biosensor technology for in-depth characterization of biomolecular interactions. Alto, the world’s first digital high-throughput benchtop SPR instrument, is capable of accelerating drug discovery using a fraction of sample volume traditionally required for biomolecular interaction analyses. Alto helps biotechnology and pharmaceutical companies go-to-market faster with increased efficiency and success early in their product pipelines. Join us on our mission to improve human life by helping scientists to succeed. For job opportunities, see our webpage at https://nicoyalife.com/about/careers/
We are transforming music into medicine. LUCID creates digital therapeutics using cutting-edge Emotion AI to improve health & wellness through the power of music. We're developing accessible and personalized digital therapeutics for a range of health conditions - including Anxiety, Alzheimer's, Paediatric Stress, Burnout, Tinnitus, and more
Phenomic is an innovative biotech company based in Boston and Toronto that specializes in developing new medicines targeting the tumor stroma. The tumor stroma is a dense web of connective tissue that surrounds solid tumors and plays a crucial role in treatment resistance and disease progression. Phenomic's scTx platform contains an extensive and optimally-curated atlas of single-cell cancer and normal tissue data and is powered by proprietary machine learning software to provide unparalleled insight into target expression and selectivity. Using scTx, Phenomic can identify exquisitely selective targets that can directly reprogram the tumor microenvironment or deliver cancer-killing payloads such as immune engagers and antibody-drug conjugates. Additionally, Phenomic has developed tumor stroma-specific experimental systems, including co-culture and disease-relevant in vivo models, to dissect stromal biology and maximize the likelihood of clinical success. Phenomic's lead program targets a novel extracellular matrix protein identified by scTx that is highly tumor selective and expressed by a pathogenic subtype of cancer-associated fibroblasts we term ecmCAFs. We have demonstrated clear in vivo proof-of-concept for this program building our conviction in scTx’s ability to identify novel high-impact, druggable targets.
BenchSci’s vision is to bring novel medicine to patients 50% faster by 2025. To achieve this, we're exponentially increasing the speed and quality of life-saving research by empowering scientists with the world’s most advanced biomedical artificial intelligence. Backed by F-Prime, Gradient Ventures (Google’s AI fund), Inovia Capital, and TCV, our platform accelerates science at 16 of the top-20 pharmaceutical companies, and over 4,300 leading research centers worldwide. We’re a remote-first company recognized for our impact and culture as a Deloitte Tech Fast 50TM, CIX Top 10 Growth, Great Place to Work®, and top-ranked organization on Glassdoor.
Vital was created to enable proactive, preventative, and accessible healthcare. We're starting with a radically disruptive approach to lab testing. Backed by many years of R&D by world-class scientists and engineers, we are a team of collaborators, re-engineering the nature of care delivery.
Novel Biotechnology is a Synthetic Biology company focused on developing highly productive pDNA manufacturing platform. We also provide CRDMO and plasmid DNA manufacturing services to our clients
At Horizon Therapeutics, we believe science and compassion must work together to transform lives. We are driven to deliver innovative medicines to those living with rare, autoimmune and severe inflammatory diseases because we uniquely understand the patient journey. For us, success is measured by the numbers that matter most – the number of lives we touch, the number we change and those we work to help save.
ProteinQure is a revenue-generating software platform for computational protein drug discovery. We combine molecular simulations, machine learning, and quantum computing to do the structure-based design of drugs. These physics-based methods make us less dependent on large data sets and that allows us to explore novel protein structures and interactions. We use our computational platform (as well as wetlab validation) to solve our partners drug design challenges and deliver new therapeutic candidates. We have a very diverse team of multi-disciplinary scientists and engineers. We are based in Toronto, Canada and are funded by top tier venture firms. If you are interested in building the next generation of computational biology tools we hope you will join us.
Affinity Biologicals, Inc. is a primary manufacturer of products used worldwide in thrombosis and hemostasis research and diagnostics. Our products include an extensive line of antibodies, conjugates, antibody pairs for immunoassay of human and animal analytes, the VisuLize line of complete ELISA kits, and a full line of human plasma products including VisuDep Immune-Depleted Factor-Deficient Plasmas, VisuCal Calibrator Plasma and VisuCon Control Plasmas. Services include protein purification, antibody production, assay development, custom manufacturing including custom lyophilization and proficiency testing materials. For more information please visit www.affinitybiologicals.com.
Quanticate is a leading global data focused clinical research organisation (CRO) primarily focused on the management, analysis and reporting of data from clinical trials and post-marketing surveillance. As experts in clinical data, Quanticate provides high quality teams that offer efficient outsourcing solutions for: • Clinical Data Management • Biostatistics • SAS Programming • Data quality oversight via Centralized Statistical Monitoring • Medical writing • Pharmacovigilance Quanticate can offer study level support, functional service provision (FSP), strategic full data-services solutions or technical consultancy to meet the needs of pharmaceutical, biotechnology and device companies across the globe. Quanticate has become the supplier of choice for many companies from top tier pharmaceutical giants through to niche biotechnology and device companies.
Avicanna is a Canadian international commercial-stage biopharmaceutical company. Focused on the advancement and commercialization of evidence-based cannabinoid-based products for the global medical and pharmaceutical market segments. Avicanna has an established scientific platform including R&D and clinical development that has led to the commercialization of more than thirty products across five market segments: MyMedi.ca Medical Cannabis Care Portal, Medical Cannabis & Wellness Products, Cosmetic & Skincare, Pharmaceutical Pipeline, and Active Pharmaceutical Ingredients (API).
Geneseeq is a research-driven company providing cutting-edge next-generation sequencing (NGS) technology to accelerate precision cancer care. We offer both pan-cancer panels analyzing 400+ genes and cancer-type specific gene panels for all sample types to help match a patient to the optimal treatment, including targeted therapy and immunotherapy. We have 1000+ research projects with biopharma and research partners, providing high-quality genomic data to accelerate translational research. Our headquarters are located in both Canada and China. Our CAP/CLIA accredited clinical laboratory is equipped with multiple advanced NGS sequencing platforms. We work closely with you to solve your specific needs, with a relentless focus on quality and efficiency. Let’s accelerate precision cancer care, together.
BlueRock Therapeutics is a leading engineered cell therapy company with a mission to develop regenerative medicines for intractable diseases. BlueRock Therapeutics’ cell+gene platform harnesses the power of cells to create new medicines for neurology, cardiology, and immunology indications. BlueRock Therapeutics’ cell differentiation technology recapitulates the cell’s developmental biology to produce authentic cell therapies, which are further engineered for additional function. Utilizing these cell therapies to replace damaged or degenerated tissue brings the potential to restore or regenerate lost function. BlueRock’s culture is defined by scientific innovation, the highest ethical standards and an urgency to bring transformative treatments to all who would benefit. The company strives to be a top employer of scientific talent, empowering every member of the team to make meaningful and lasting contributions to the burgeoning field of regenerative medicine. Become a BlueRocker! We are expanding our BlueRock team at all locations. Contact us via LinkedIn or our website to learn about rewarding career opportunities.
Deep Genomics is using artificial intelligence to build a new universe of life-saving genetic therapies. The future of medicine will rely on artificial intelligence, because biology is too complex for humans to understand. At Deep Genomics, our geneticists, molecular biologists and chemists develop new ways of detecting and treating disease using our biologically accurate artificial intelligence technology.
Reunion Neuroscience is committed to innovating therapeutic solutions to treat mental health conditions through the development of novel psychedelic compounds
Geneseeq is a research-driven company providing cutting-edge next-generation sequencing (NGS) technology to accelerate precision cancer care. We offer both pan-cancer panels analyzing 400+ genes and cancer-type-specific gene panels for all sample types to help match a patient to the optimal treatment, including targeted therapy and immunotherapy for solid tumors and blood cancers. Additionally, we develop cutting-edge technologies and kits for minimal residual disease (MRD) monitoring and multi-cancer early detection (MCED). Our testing services are conducted in our CAP/CLIA/ISO15189-accredited laboratory, where we manufacture IVD and RUO testing kits for in-house solutions. With a global reach, our headquarters are located in both Canada and China. Our products and services are well-established and ordered by over 8,000 long-term oncologist partners across 12+ countries and regions. We are engaged in 2,200+ research projects with biopharma and research partners, providing high-quality genomic data to accelerate translational research. We work closely with our partners to address their specific needs, maintaining a relentless focus on quality and efficiency.
Toronto-based infectious disease intelligence company, BlueDot, has developed a first-of-its-kind, global early warning technology for infectious diseases. Using artificial and human intelligence, BlueDot’s outbreak risk platform tracks over 120 infectious diseases globally in 65 languages, around the clock and anticipates their spread and impact. They empower national and international health agencies, pharma and life sciences companies, and businesses to better anticipate, and respond to, emerging threats. BlueDot was among the first in the world to identify the emerging risk from, and publish a scientific paper on, COVID-19, and delivers regular critical Insights to its partners and customers worldwide to mobilize timely, effective, efficient, coordinated, and measured responses. BlueDot was founded in 2013 by Dr. Kamran Khan, a practicing infectious disease physician, and Professor of Medicine with the Division of Infectious Diseases at the University of Toronto. Motivated by his experiences as a frontline healthcare worker during the 2003 Toronto SARS outbreak, Dr. Khan has been studying the outbreak of infectious diseases over the past 15 years to lay the scientific foundation for BlueDot’s early warning system.
One trocar, three sizes, countless advantages
Work Your Passion. Live Your Purpose.
